An observational study in Spinal Muscle Atrophy, sponsored by Hoffmann-La Roche. Recruiting at 2 sites in Egypt. Open to participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Hoffmann-La Roche · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche — 1 open to participants now, 4 under way, none of them phase 3. Muscular Atrophy, Spinal · Hoffmann-La Roche.
Among the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche, this one is the only one that started in 2026, is one of 2 observational ones, and was the 18th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.
Browse Muscular Atrophy, Spinal studies →1 of the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche is open now, in 1 country.
By country, each count listing its studies:
Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.
This study: Up to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 1 · Phase 4 3
First in 2013; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 30 is below the median of 139 across 114 observational studies indexed under Muscular Atrophy, Spinal.
Median enrollment 35 across the 15 interventional studies, 33 across the 2 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, non-interventional, prospective study with a retrospective component aims to evaluate the real-world clinical outcomes, safety profile, and motor function improvements of Risdiplam treatment in participants with Type I and Type II Spinal Muscle Atrophy over 24 months of treatment.
The study will allow retrospective collection of medical history data and previous participants visits from the medical records.
The participants must have a confirmed diagnosis of 5q-autosomal recessive SMA type I or type II with at least two survival motor neuron 2 (SMN2) copies for which Risdiplam is prescribed as per the SmPC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Data will be collected before, during and after treatment from participants who receive risdiplam treatment according to standard of care and Summary of Product Characteristics (SmPC). Participant data will be collected only during routine clinical interactions, with no additional study visits mandated.
Change From Index Date in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Score at Month 12
CHOP-INTEND assessment is performed for participants aged \<2 years or aged \>2 years who are not able to sit \> 10 seconds as defined by the World Health Organization (WHO). Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. The index date (D1) is when the participant was administered the first dose of Risdiplam.
Time frame: Baseline, Month 12
Change From Index Date in Hammersmith Functional Motor Scale Expanded (HFMSE) Score at Months 12
HFMSE assessment is performed for participants who are ≥ 2 years and are sitters or walkers. Items on the original HFMS were expanded to capture higher functioning in SMA patients using 13 relevant additional items adapted from the gross motor function measure (GMFM) with their scoring adapted to a three-point scale as in the original HFMS. The score ranges between 0 - 66, a higher score indicates a higher level of function. The index date (D1) is when the participant was administered the first dose of Risdiplam.
Time frame: Baseline, Months 12
Change From Index Date in CHOP-INTEND Score at Month 24
CHOP-INTEND assessment is performed for participants aged \<2 years or aged \>2 years who are not able to sit \> 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. The index date (D1) is when the participant was administered the first dose of Risdiplam.
Time frame: Baseline, Month 24
Percentage of Participants with CHOP-INTEND Score Improvement ≥ 4 Points Compared to Index Date at Months 12 and 24
CHOP-INTEND assessment is performed for participants aged \<2 years or aged \>2 years who are not able to sit \> 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. The index date (D1) is when the participant was administered the first dose of Risdiplam.
Time frame: Baseline, Months 12 and 24
Percentage of Participants with CHOP-INTEND Score ≥ 40 at Months 12 and 24
CHOP-INTEND assessment is performed for participants aged \<2 years or aged \>2 years who are not able to sit \> 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal orientated items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes.
Time frame: At Months 12 and 24
Change From Baseline in HFMSE Score at Month 24
HFMSE assessment is performed for participants who are ≥ 2 years and are sitters or walkers. Items on the original HFMS were expanded to capture higher functioning in SMA patients using 13 relevant additional items adapted from the GMFM with their scoring adapted to a three-point scale as in the original HFMS. The score ranges between 0 - 66, a higher score indicates a higher level of function. Baseline visit correspond with the index date (D1) where the participant was administered the first dose of Risdiplam.
Time frame: Baseline, Month 24
Number of Participants who Require Ventilatory Assistance
Invasive ventilation and non-invasive ventilation due to respiratory insufficiency. Participants on permanent ventilation and when using it as temporary respiratory support will be assessed.
Time frame: Up to 2 years follow-up per participant
Duration of Ventilation
Number of hours spent per day of non-invasive or invasive ventilation. Duration for both permanent ventilation and when used as temporary respiratory support will be assessed.
Time frame: Up to 2 years follow-up per participant
Time Until Permanent Ventilation
Time until permanent ventilation is defined as ≥ 16 hours of non-invasive ventilation per day or intubation for \> 21 consecutive days in the absence of, or following the resolution of, an acute reversible event or tracheostomy.
Time frame: Up to 2 years follow-up per participant
Overall Survival at Month 24
Time frame: At Month 24
Ventilation-free Survival
Assessed by duration of time from a specified index date until the initiation of permanent ventilation.
Time frame: Up to 2 years follow-up per participant
Change From Baseline in Growth Pattern
Growth patterns will be compared to standardized growth charts.
Time frame: Up to Month 24
Number of Participants With Musculoskeletal Abnormalities
Musculoskeletal abnormalities include scoliosis, kyphosis or other deformities
Time frame: Up to Month 24
Time to Loss of Swallowing Function Assessed by the Study Physician
Time frame: Up to Month 24
Bulbar Function as Assessed by the Study Physician Versus Baseline
Bulbar function measures the ability to feed orally, chew, and ability to swallow versus baseline data. It also assesses the speaking and crying functions of the participant.
Time frame: Up to Month 24
Number of Participants With Adverse Events (AE) Serious Adverse Events (SAE)
Data for incidence, seriousness, severity, and relatedness of all AEs reported or documented in medical notes by physicians during the safety observation period will also be reported.
Time frame: Up to 2 years follow-up per participant
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Mar 2028, 19 months after the start.
Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 19 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.